Neumedicines Oncology and Hematology Drug Candidates Featured in BIOWORLD Magazine

Pasadena, CA (PRWEB) June 06, 2011

Neumedicines, an independently held drug discovery and development company concentrated on ingenious protein treatments for the treatment of hematopoietic deficiencies, cancer cells and autoimmune illness, announced today that a profile of the company and its pipeline of oncology and hematology medicine prospects is featured in the most current issue of BioWorld, among the most extensively review publications in the pharma and biotech industries. The article can be acquired at http://www.bioworld.com. . The publication kept in mind that

, Taking opportunity from the failure of others, Neumedicines Inc. is rejuvenating Interleukin-12( IL-12), a biologic as soon as seen as the great hope for cancer cells. The Pasadena, Calif.-based company launched a Phase I safety trial Thursday for its lead candidate, HemaMax, a key regulatory authority of the hematopoietic system. Initially, the trial will enlist about 40 targets, but Neumedicines aims to broaden its safety database to cover up to 500 volunteers from diverse populations. . The article likewise kept in mind: Neumedicines has huge strategies for its lead candidate.

The company is dealing with the protocol for a Stage I cancer cells research with the BEGINNING Center in San Antonio and intends to file an investigational brand-new medicine application in the fall for pancreatic cancer cells. . Dr. Lena Basile, Neumedicines Chief Executive Policeman stated, We are pleased to get acknowledgment from a worldwide biotech publication for our lead pipeline item, HemaMax, that has shown durable and broad hematopoietic recovery in lethally irradiated animal models in addition to in tumor-bearing animals treated with radiation and radiation treatment. . We anticipate the results of our Phase I HemaMax medical trial which we expect by February 2012, Dr. Basile included.

. About BioWorld Today . BioWorld Today, the news source of record for the biotechnology industry, is read by biotechnology specialists worldwide for its powerful, objective information reporting. BioWorld Today is provided by means of e-mail every business morning, and is also found exclusively online at http://www.bioworld.com. The BioWorld online website has actually been globally acknowledged as the most comprehensive resource for strategic biotechnology information and details readily available today. . About Neumedicines Inc. . Neumedicines Inc. is an independently held, early-stage business developing protein therapeutics that take care of unmet clinical and societal

requirements in the fields of oncology, hematology, and immunology. The business lead product prospect, NMIL12-1 (recombinant human interleukin-12; rHuIL-12 ), functions regarding target several pathways of hematopoiesis and innate immunity and is being developed to address an array of clinical indicators. At Neumedicines, we are committed to developing and making best use of the scientific, clinical, and commercial capacity of our item pipeline. . Neumedicines is developing NMIL12-1 under the brand HemaMax as a biodefense radiation clinical countermeasure. NMIL12-1 is also being developed for

indications in hematology/oncology, such as chemotherapy-induced thrombocytopenia. The company operates from its head office and labs in Pasadena, California. . For even more info see: http://www.neumedicines.com . Follow Neumedicines on Twitter @ Neumedicines . This press release contains specific forward-looking

statements connecting to our business. Actual events or outcomes might differ from the expectations set forth herein as an outcome of a variety of

elements, consisting of uncertainties inherent in pre-clinical studies, clinical trials and product development programs. There can be no guarantee that any product in Neumedicines pipeline will be effectively established or manufactured, that outcomes of clinical studies will be encouraging of regulative approvals required to market licensed items, or that any of the forward-looking info offered herein will be shown accurate. . Investor and partnership makes inquiries please contact: Dr. Lena Basile at 626-844-3800 or basile(at )neumedicines(dot) com . Media members please contact: Jeff Richardson at 805-491-8313 or jeff (at) richardsonglobalpr(

dot)com . # # # . . . . .